Clinical Trial Update: A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating GLPG3970 as an oral treatment for 6 weeks in adults with moderately to severely active rheumatoid arthritis who had an inadequate respo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GLPG3970 (GLPG3970)

Snippet

Sponsor: Galapagos NV | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2022-07-18